SNSS - Sunesis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
34.6M
Enterprise Value 3
19.96M
Trailing P/E
N/A
Forward P/E 1
-0.97
PEG Ratio (5 yr expected) 1
-0.01
Price/Sales (ttm)
Price/Book (mrq)
1.69
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
-0.84

Trading Information

Stock Price History

Beta (5Y Monthly) 2.70
52-Week Change 3-4.62%
S&P500 52-Week Change 324.46%
52 Week High 31.7700
52 Week Low 30.2000
50-Day Moving Average 30.4629
200-Day Moving Average 30.6950

Share Statistics

Avg Vol (3 month) 31.62M
Avg Vol (10 day) 36.78M
Shares Outstanding 5111.32M
Float 74.86M
% Held by Insiders 10.31%
% Held by Institutions 149.97%
Shares Short (Nov 29, 2019) 42.33M
Short Ratio (Nov 29, 2019) 41.67
Short % of Float (Nov 29, 2019) 44.00%
Short % of Shares Outstanding (Nov 29, 2019) 42.09%
Shares Short (prior month Oct 31, 2019) 41.13M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 26/1
Last Split Date 3Sep 8, 2016

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-46.87%
Return on Equity (ttm)-115.61%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)237k
EBITDA -23.68M
Net Income Avi to Common (ttm)-24.04M
Diluted EPS (ttm)-0.3500
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)32.81M
Total Cash Per Share (mrq)0.29
Total Debt (mrq)6.41M
Total Debt/Equity (mrq)19.86
Current Ratio (mrq)4.56
Book Value Per Share (mrq)0.18

Cash Flow Statement

Operating Cash Flow (ttm)-24.94M
Levered Free Cash Flow (ttm)-21.86M